A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming
Abstract Melanoma, being one of the most dangerous forms of skin cancer, is characterized by its aggressive and metastatic nature, with the potential to develop resistance to various treatments. This resistance makes the disease challenging to treat, emphasizing the need for new treatment strategies...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03781-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699652034625536 |
|---|---|
| author | Mina Afrashteh Nour Mansour Rajabivahid Marjan Sadat Seyed Mehdi Safa Tahmasebi Sepideh Nasirzadeh Dashtgol Mahmoud Dehghani-Ghorbi Ahmad Ghorbani Vanan Farid Ghorbaninezhad |
| author_facet | Mina Afrashteh Nour Mansour Rajabivahid Marjan Sadat Seyed Mehdi Safa Tahmasebi Sepideh Nasirzadeh Dashtgol Mahmoud Dehghani-Ghorbi Ahmad Ghorbani Vanan Farid Ghorbaninezhad |
| author_sort | Mina Afrashteh Nour |
| collection | DOAJ |
| description | Abstract Melanoma, being one of the most dangerous forms of skin cancer, is characterized by its aggressive and metastatic nature, with the potential to develop resistance to various treatments. This resistance makes the disease challenging to treat, emphasizing the need for new treatment strategies. Within the tumor microenvironment (TME), melanoma cells exploit metabolic shifts, particularly glycolysis, to create an immunosuppressive TME that prevents dendritic cells (DCs) from functioning properly. Essential metabolic alterations such as lactate and lipid accumulation, and lack of tryptophan disrupt DC maturation, antigen presentation, and T cell activation. In recent years, melanoma immunotherapy has increasingly focused on reprogramming the metabolism of DCs. This review paper aims to provide insights into the metabolic suppression of melanoma-associated DCs, allowing the design of therapeutic strategies based on metabolic interventions to promote or restore DC function. This contribution reviews the metabolic reprogramming of DCs as a new approach for melanoma immunotherapy. |
| format | Article |
| id | doaj-art-8b8cd273b3974711bd0bad3a352dfe1c |
| institution | DOAJ |
| issn | 1475-2867 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-8b8cd273b3974711bd0bad3a352dfe1c2025-08-20T03:18:31ZengBMCCancer Cell International1475-28672025-04-0125111610.1186/s12935-025-03781-3A new era in melanoma immunotherapy: focus on DCs metabolic reprogrammingMina Afrashteh Nour0Mansour Rajabivahid1Marjan Sadat Seyed Mehdi2Safa Tahmasebi3Sepideh Nasirzadeh Dashtgol4Mahmoud Dehghani-Ghorbi5Ahmad Ghorbani Vanan6Farid Ghorbaninezhad7Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical SciencesDepartment of Internal Medicine, Valiasr Hospital, Zanjan University of Medical SciencesStudent Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical SciencesStudent Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical SciencesDepartment of Medical Laboratory Sciences, School of Paramedical Sciences, Tehran Medical Branch, Islamic Azad UniversityHematology-Oncology Department, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical SciencesStudent Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical SciencesStudent Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical SciencesAbstract Melanoma, being one of the most dangerous forms of skin cancer, is characterized by its aggressive and metastatic nature, with the potential to develop resistance to various treatments. This resistance makes the disease challenging to treat, emphasizing the need for new treatment strategies. Within the tumor microenvironment (TME), melanoma cells exploit metabolic shifts, particularly glycolysis, to create an immunosuppressive TME that prevents dendritic cells (DCs) from functioning properly. Essential metabolic alterations such as lactate and lipid accumulation, and lack of tryptophan disrupt DC maturation, antigen presentation, and T cell activation. In recent years, melanoma immunotherapy has increasingly focused on reprogramming the metabolism of DCs. This review paper aims to provide insights into the metabolic suppression of melanoma-associated DCs, allowing the design of therapeutic strategies based on metabolic interventions to promote or restore DC function. This contribution reviews the metabolic reprogramming of DCs as a new approach for melanoma immunotherapy.https://doi.org/10.1186/s12935-025-03781-3Dendritic cellMelanomaMetabolic reprogrammingTumor microenvironmentImmunotherapy |
| spellingShingle | Mina Afrashteh Nour Mansour Rajabivahid Marjan Sadat Seyed Mehdi Safa Tahmasebi Sepideh Nasirzadeh Dashtgol Mahmoud Dehghani-Ghorbi Ahmad Ghorbani Vanan Farid Ghorbaninezhad A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming Cancer Cell International Dendritic cell Melanoma Metabolic reprogramming Tumor microenvironment Immunotherapy |
| title | A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming |
| title_full | A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming |
| title_fullStr | A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming |
| title_full_unstemmed | A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming |
| title_short | A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming |
| title_sort | new era in melanoma immunotherapy focus on dcs metabolic reprogramming |
| topic | Dendritic cell Melanoma Metabolic reprogramming Tumor microenvironment Immunotherapy |
| url | https://doi.org/10.1186/s12935-025-03781-3 |
| work_keys_str_mv | AT minaafrashtehnour anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT mansourrajabivahid anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT marjansadatseyedmehdi anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT safatahmasebi anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT sepidehnasirzadehdashtgol anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT mahmouddehghanighorbi anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT ahmadghorbanivanan anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT faridghorbaninezhad anewerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT minaafrashtehnour newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT mansourrajabivahid newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT marjansadatseyedmehdi newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT safatahmasebi newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT sepidehnasirzadehdashtgol newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT mahmouddehghanighorbi newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT ahmadghorbanivanan newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming AT faridghorbaninezhad newerainmelanomaimmunotherapyfocusondcsmetabolicreprogramming |